Category Archives: Ulcerative Colitis

Food Network Star, Sunny Anderson talks IBD with me! IBD the same as IBS? Does food cure IBD? Myths and Misconceptions? I sit down with Food Network Star, Sunny Anderson who has been living with Ulcerative Colitis for over 20 years. Recently... By: Sara Ringer … Continue reading →

Challenges in Surgery for Pediatric Ulcerative Colitis Patients Dedicated to the interests of the entire community of patients with inflammatory bowel disease (IBD), and designed to meet the educational needs of all healt... By: ImedexCME … Continue reading →

My story so far with Ulcerative Colitis In this video I explain my story in more depth. Sorry I keep scratching my face - I will go in to why I think I'm doing this in the next video!! By: kateellenberry … Continue reading →

Should We Change How We Position Biologics for Use in Ulcerative Colitis? Dedicated to the interests of the entire community of patients with inflammatory bowel disease (IBD), and designed to meet the educational needs of all healt... By: ImedexCME … Continue reading →

Treatment of Inpatients with Severe, Refractory Ulcerative Colitis Dedicated to the interests of the entire community of patients with inflammatory bowel disease (IBD), and designed to meet the educational needs of all healt... By: ImedexCME … Continue reading →

Can You Solve the Case: Unknowns from Colonoscopies of Ulcerative Colitis Patients Dedicated to the interests of the entire community of patients with inflammatory bowel disease (IBD), and designed to meet the educational needs of all healt... By: ImedexCME … Continue reading →

By RTT News, January 08, 2015, 01:43:00 AM EDT (RTTNews.com) - Galapagos NV (GLPGF.PK, GLPYY.PK), a Belgium-based clinical stage biotech company, announced Thursday that it has initiated a Phase 2 Proof-of-Concept study in ulcerative colitis with GPR84 inhibitor GLPG1205, a potential novel treatment for Inflammatory Bowel Diseases. GLPG1205 arises from Galapagos' target discovery platform and is fully proprietary to the company. The firm noted that GLPG1205 ('1205) inhibits GPR84, a novel mechanism of action developed by Galapagos for Inflammatory Bowel Diseases or IBD. Galapagos has shown that GPR84 plays a key role in IBD and that '1205 is a selective inhibitor of GPR84 and very effective in pre-clinical models for IBD. In Phase 1 studies, '1205 showed good safety, full blockage of GPR84, and favorable drug-like properties. The first patients in this double-blind, placebo controlled study will initiate their treatment this week. Galapagos said the clinical Proof-of-Concept Phase 2 trial for '1205 will involve approximately 60 patients with moderate to severe ulcerative colitis. The aim is to evaluate the efficacy, safety and tolerability and pharmacokinetics of '1205, and to explore the effects of '1205 on selected biomarkers in this patient population. Galapagos has received full approvals to start the trial … Continue reading →

Arena Pharmaceuticals is headquartered in San Diego. / photo by Eduardo Contreras * U-T Arena Pharmaceuticals of San Diego has successfully completed an early phase clinical trial of a potential autoimmune drug, the biotech company said Wednesday. It plans to launch further studies of the medication for the purpose of treating ulcerative colitis and Crohns disease. Arenas shares surged after the announcement, closing at $5.85, up 76 percent for the day. The companys market value rose past the billion-dollar mark to $1.3 billion, a level it hadnt reached since late June. The drug, APD334, was found in the Phase 1b clinical trial to lower the level of white blood cells called lymphocytes by up to 69 percent. The lymphocyte counts returned to their previous levels about a week after the drug was given. Lymphocyte reduction has been linked to the effectiveness of autoimmune drugs targeting multiple sclerosis, ulcerative colitis and Crohns disease, said Craig Audet, Arenas senior vice president of operations and head of global regulatory affairs. The drugs on the market now that treat these conditions have lymphocytes lowering somewhere in the range of 60 to 70 percent, and they show clinical efficacy, Audet said. Were right in the … Continue reading →

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. VIENNA --(BUSINESS WIRE)-- 22.10.2014 -- Clinical experience presented today at the Celltrion Healthcare satellite symposium during UEGW 2014 builds the evidence base for treating patients with IBD (Crohns disease and ulcerative colitis) with a biosimilar monoclonal antibody (mAb) infliximab. Infliximab is an anti-TNF therapy for treating patients with IBD1,2,, and is considered a therapy for controlling disease symptoms over the long term.3,4 Leading expert, Jrgen Jahnsen, Professor of Gastroenterology, University of Oslo, Norway, reported on his real-world clinical experience of treating people with both Crohns disease and ulcerative colitis with the first biosimilar mAb anti-TNF approved by the European Medicines Agency (EMA) and licensed for use in Norway. A statistically significant reduction in disease activity at week fourteen was reported in 46 IBD patients (26 Crohns and 20 ulcerative colitis) following treatment with three infusions. Commenting on his experience Prof Jahnsen said, Whilst biologics have become increasingly important as a treatment option in IBD, they are also expensive which may mean that some patients have had limited access to them. The availability of a biosimilar anti-TNF could contribute to improving patient access to advanced biologic treatments. … Continue reading →

Ulcerative Colitis Characteristics By: Ahmed Diaa … Continue reading →